Latest news

• Vernalis accepts £33m takeover offer from Ligand Pharma

  and aminopeptidase inhibitor tosedostat for leukaemia, which is partnered with CTI Biopharma.

• CTI slumps as Servier-partnered lymphoma drug fails

  gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve progression-free survival (PFS), its primary endpoint. ... conditional, with CTI required to submit the results to the EMA by the end of this year in support of its

• Baxalta and CTI complete filing for Jakafi rival in US

  dose of Novartis/Incyte's drug, which according to CTI accounts for the bulk of patients taking Jakafi in the US. ... Baxalta's former parent company Baxter  licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m.

• Baxter and CTI's Jakafi rival clears phase III trial

  Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal. ... Assuming positive results in both PERSIST trials CTI has predicted it could be in a position to file for approval of pacritinib later this year or early in

• CTI launches cancer drug Pixuvri in UK

  Nevertheless, the recommendation was an important one for CTI and the UK lymphoma community, paving the way for yesterday's launch. ... it any, effective treatment options,' said CTI's president and CEO Dr James Bianco.